Search
Levosemotiadil
go.drugbank.com/drugs/DB20446ExperimentalThe usage of the INN stem '-dil' in the name indicates that Levosemotiadil is a vasodilator. Levosemotiadil has a monoisotopic molecular weight of 536.2 Da.
Ipramidil
go.drugbank.com/drugs/DB20454ExperimentalThe usage of the INN stem '-dil' in the name indicates that Ipramidil is a vasodilator. Ipramidil has a monoisotopic molecular weight of 256.12 Da.
Pexantel
go.drugbank.com/drugs/DB20771ExperimentalThe usage of the INN stem '-antel' in the name indicates that Pexantel is a anthelminthic. Pexantel has a monoisotopic molecular weight of 210.17 Da.
Zilantel
go.drugbank.com/drugs/DB20793ExperimentalThe usage of the INN stem '-antel' in the name indicates that Zilantel is a anthelminthic. Zilantel has a monoisotopic molecular weight of 664.11 Da.
Belfosdil
go.drugbank.com/drugs/DB21327ExperimentalThe usage of the INN stem '-dil' in the name indicates that Belfosdil is a vasodilator. Belfosdil has a monoisotopic molecular weight of 548.3 Da.
Litomeglovir
go.drugbank.com/drugs/DB21363ExperimentalThe usage of the INN stem '-vir' in the name indicates that Litomeglovir is a antiviral. Litomeglovir has a monoisotopic molecular weight of 498.19 Da.
Norgesterone
go.drugbank.com/drugs/DB21409ExperimentalThe usage of the INN stem '-terone' in the name indicates that Norgesterone is a antiandrogen. Norgesterone has a monoisotopic molecular weight of 300.21 Da.
Pitenodil
go.drugbank.com/drugs/DB21442ExperimentalThe usage of the INN stem '-dil' in the name indicates that Pitenodil is a vasodilator. Pitenodil has a monoisotopic molecular weight of 353.18 Da.
Tirfipiravir
go.drugbank.com/drugs/DB21648ExperimentalThe usage of the INN stem '-vir' in the name indicates that Tirfipiravir is a antiviral. Tirfipiravir has a monoisotopic molecular weight of 355.1 Da.
ChulaCov19 mRNA vaccine
go.drugbank.com/drugs/DB16445ExperimentalThe ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678]. … The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.